Prelude Therapeutics, Lilly to Test Experimental Drug in Phase 1 Trial
Prelude Therapeutics announced a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722 alongside two Lilly medicines for breast cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Prelude and Lilly Agree on Trial Collaboration and Drug Supply
The companies will evaluate Prelude's KAT6A selective degrader PRT13722 with Verzenio and Inluriyo in patients with HR+/HER2- breast cancer.